Volume 5, Issue 5, Pages e231-e240 (May 2018)

Slides:



Advertisements
Similar presentations
Sulfamethoxazole/Trimethoprim/Isoniazid/Pyridoxine scored tablets are bioequivalent to individual products and are acceptable to patients with advanced.
Advertisements

Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy.
Volume 390, Issue 10099, Pages (September 2017)
Volume 4, Issue 10, Pages e465-e474 (October 2017)
12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely.
Volume 380, Issue 9845, Pages (September 2012)
Volume 390, Issue 10089, Pages (July 2017)
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
Dr G Musoro and the REALITY trial team
Volume 388, Issue 10059, Pages (November 2016)
Sarah L. Pett1, Lewis Haddow2, Ruth Nhema3, Moira Spyer1, Laura Benjamin2, Grace Najjuka4, Ibrahim Daud5, Jay Berkley6, Juliet Kitabalwa4, James Hakim3,
Figure 1: Rates of fatal events over time from ART initiation
Diana M Gibb on behalf of the REALITY trial team
Abraham Siika1, Leanne McCabe2, Mutsa Bwakura-Dangarembizi3, Cissy Kityo4, Jane Mallewa5, Kath Maitland6, Anna Griffiths2, Keith Baleeta7, Shepherd Mudzingwa3,
12-week raltegravir-intensified quadruple therapy versus triple first-line ART reduces viral load more rapidly but does not reduce mortality in severely.
Volume 388, Issue 10059, Pages (November 2016)
Cissy Kityo1, A. Sarah Walker2, Immaculate Nankya1, Moira Spyer2, Eva Nabulime1, Mutsa Bwakura-Dangarembizi3, Linda Mipando4,
Volume 392, Issue 10145, Pages (August 2018)
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses 
An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled.
Volume 4, Issue 10, Pages e465-e474 (October 2017)
Volume 15, Issue 4, Pages (April 2014)
Volume 373, Issue 9663, Pages (February 2009)
Volume 4, Issue 2, Pages (February 2017)
Volume 4, Issue 3, Pages e105-e112 (March 2017)
Montelukast for postinfectious cough in adults: a double-blind randomised placebo- controlled trial  Dr Kay Wang, DPhil, Surinder S Birring, MD, Kathryn.
Volume 17, Issue 9, Pages (September 2016)
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
Volume 392, Issue 10141, Pages (July 2018)
Volume 12, Issue 7, Pages (July 2011)
Volume 3, Issue 12, Pages e592-e600 (December 2016)
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group,
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study  William.
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST):
Volume 381, Issue 9875, Pages (April 2013)
Volume 18, Issue 3, Pages (March 2017)
Effectiveness of the Healthy Lifestyles Programme (HeLP) to prevent obesity in UK primary-school children: a cluster randomised controlled trial  Jenny.
Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind,
Volume 388, Issue 10059, Pages (November 2016)
Volume 390, Issue 10099, Pages (September 2017)
Volume 380, Issue 9845, Pages (September 2012)
The eSexual Health Clinic system for management, prevention, and control of sexually transmitted infections: exploratory studies in people testing for.
Volume 387, Issue 10013, Pages (January 2016)
Volume 19, Issue 4, Pages (April 2018)
Volume 375, Issue 9709, Pages (January 2010)
Volume 392, Issue 10144, Pages (July 2018)
The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial  Dr.
Volume 390, Issue 10089, Pages (July 2017)
Volume 18, Issue 8, Pages (August 2017)
Volume 4, Issue 8, Pages e341-e348 (August 2017)
Volume 2, Issue 10, Pages e417-e426 (October 2015)
Volume 392, Issue 10162, Pages (December 2018)
Volume 14, Issue 6, Pages (May 2013)
Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study  Krishna P Reddy,
Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised.
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled.
Volume 375, Issue 9722, Pages (April 2010)
Effect of non-monetary incentives on uptake of couples' counselling and testing among clients attending mobile HIV services in rural Zimbabwe: a cluster-randomised.
Volume 389, Issue 10068, Pages (February 2017)
Volume 18, Issue 10, Pages (October 2017)
Effect of co-trimoxazole on mortality in HIV-exposed but uninfected children in Botswana (the Mpepu Study): a double-blind, randomised, placebo-controlled.
Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational,
Volume 393, Issue 10177, Pages (March 2019)
Volume 372, Issue 9632, Pages (July 2008)
Volume 5, Issue 1, Pages (January 2018)
Volume 388, Issue 10059, Pages (November 2016)
Volume 18, Issue 6, Pages (June 2019)
Effect of strikes by health workers on mortality between 2010 and 2016 in Kilifi, Kenya: a population-based cohort analysis  Gerald Ong'ayo, MBChB, Michael.
Volume 20, Issue 7, Pages (July 2019)
Presentation transcript:

Volume 5, Issue 5, Pages e231-e240 (May 2018) Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open- label, parallel-group, randomised controlled trial  Jane Mallewa, FRCP, Alexander J Szubert, MSc, Prof Peter Mugyenyi, FRCP, Ennie Chidziva, MSc, Margaret J Thomason, PhD, Priscilla Chepkorir, MPH, George Abongomera, MSc, Keith Baleeta, MBChB, Anthony Etyang, MMed, Colin Warambwa, MBChB, Betty Melly, BSc, Shepherd Mudzingwa, BPharm, Christine Kelly, PhD, Clara Agutu, MPH, Helen Wilkes, MSc, Sanele Nkomani, MSc, Victor Musiime, PhD, Abbas Lugemwa, MD, Sarah L Pett, PhD, Mutsa Bwakura-Dangarembizi, MMed, Andrew J Prendergast, DPhil, Prof Diana M Gibb, MD, Prof A Sarah Walker, PhD, Prof James A Berkley, FRCPCH Peter Mugyenyi, Cissy Kityo, Victor Musiime, Priscilla Wavamunno, Esther Nambi, Paul Ocitti, Milly Ndigendawani, Sheila Kabahenda, Mable Kemigisa, Juliet Acen, David Francis Olebo, Gordon Mpamize, Alex Amone, David Okweny, Andrew Mbonye, Florence Nambaziira, Angela Rweyora, Mary Kangah, Beatrice Kabaswahili, James Abach, George Abongomera, Joseph Omongin, Irene Aciro, Aleti Philliam, Beatrice Arach, Emmanuel Ocung, Geoffrey Amone, Peter Miles, Claudia Adong, Constance Tumsuiime, Patrick Kidega, Ben Otto, Florence Apio, Keith Baleeta, Andrew Mukuye, Mary Abwola, Fred Ssennono, David Baliruno, Stephen Tuhirwe, Ronald Namisi, Fredrick Kigongo, Dickson Kikyonkyo, Furaha Mushahara, David Okweny, Julian Tusiime, Alex Musiime, Agnes Nankya, Dickens Atwongyeire, Sowal Sirikye, Sula Myalo, Nelson Noowe, Abbas Lugemwa, Mariam Kasozi, Sandra Mwebe, Lorna Atwine, Tapson Senkindu, Ian Natuhurira, Chrispus Katemba, Emily Ninsiima, Moses Acaku, Joy Kyomuhangi, Rogers Ankunda, Deogratious Tukwasibwe, Lillian Ayesiga, James Hakim, Kusum Nathoo, Mutsa Bwakura-Dangarembizi, Andrew Reid, Ennie Chidziva, Tawand Mhute, Gloria Tinago, Joyline Bhiri, Shepherd Mudzingwa, Misheck Phiri, John Steamer, Ruth Nhema, Colin Warambwa, Godfrey Musoro, Shirley Mutsai, Beauty Nemasango, Columbus Moyo, Stuart Chitongo, Kennias Rashirai, Sydney Vhembo, Brian Mlambo, Sanele Nkomani, Buxton Ndemera, Marko Willard, Chipo Berejena, Yeukai Musodza, Patience Matiza, Boniface Mudenge, Vongai Guti, Anthony Etyang, Clara Agutu, Jay Berkley, Kathryn Maitland, Patricia Njuguna, Shalton Mwaringa, Timothy Etyang, Ken Awuondo, Stephen Wale, Jimmy Shangala, Jefwa Kithunga, Salim Mwarumba, Salma Said Maitha, Robert Mutai, Margaret Lozi Lewa, Gabriel Mwambingu, Alfred Mwanzu, Connie Kalama, Helen Latham, Joyce Shikuku, Amos Fondo, Anne Njogu, Connie Khadenge, Bryan Mwakisha, Abraham Siika, Kara Wools-Kaloustian, Winston Nyandiko, Priscilla Chepkorir-Cheruiyot, Allan Sudoi, Simon Wachira, Betty Meli, Mercy Karoney, Agnes Nzioka, Michael Tanui, Martha Mokaya, Wilson Ekiru, Chris Mboya, Dorothy Mwimali, Cecilia Mengich, Julie Choge, Wilfred Injera, Kennedy Njenga, Salinah Cherutich, Millicent Anyango Orido, Gerald Omondi Lwande, Peter Rutto, Alice Mudogo, Irene Kutto, Amina Shali, Linda Jaika, Hellen Jerotich, Mowlem Pierre, Jane Mallewa, Symon Kaunda, Joep Van Oosterhout, Bernadette O'Hare, Robert Heydermann, Carmen Gonzalez, Nettie Dzabala, Christine Kelly, Brigitte Denis, George Selemani, Linda Nyondo- Mipando, Emmie Chirwa, Peter Banda, Linley Mvula, Harrison Msuku, Milton Ziwoya, Yollam Manda, Simon Nicholas, Clemens Masesa, Thandi Mwalukomo, Lumbani Makhaza, Irene Sheha, Joseph Bwanali, Molly Limbuni, Diana M Gibb, Margaret J Thomason, Ann Sarah Walker, Sarah L Pett, Alexander J Szubert, Anna Griffiths, Helen Wilkes, Chathurika Rajapakse, Moira J Spyer, Andrew J Prendergast, Nigel Klein, Mary Rauchenberger, Nadine Van Looy, Emma Little, Keith Fairbrother, Frances Cowan, Janet Seeley, Sarah Bernays, Rachel Kawuma, Zivai Mupambireyi Jane Mallewa, FRCP, Alexander J Szubert, MSc, Prof Peter Mugyenyi, FRCP, Ennie Chidziva, MSc, Margaret J Thomason, PhD, Priscilla Chepkorir, MPH, George Abongomera, MSc, Keith Baleeta, MBChB, Anthony Etyang, MMed, Colin Warambwa, MBChB, Betty Melly, BSc, Shepherd Mudzingwa, BPharm, Christine Kelly, PhD, Clara Agutu, MPH, Helen Wilkes, MSc, Sanele Nkomani, MSc, Victor Musiime, PhD, Abbas Lugemwa, MD, Sarah L Pett, PhD, Mutsa Bwakura-Dangarembizi, MMed, Andrew J Prendergast, DPhil, Prof Diana M Gibb, MD, Prof A Sarah Walker, PhD, Prof James A Berkley, FRCPCH Peter Mugyenyi, Cissy Kityo, Victor Musiime, Priscilla Wavamunno, Esther Nambi, Paul Ocitti, Milly Ndigendawani, Sheila Kabahenda, Mable Kemigisa, Juliet Acen, David Francis Olebo, Gordon Mpamize, Alex Amone, David Okweny, Andrew Mbonye, Florence Nambaziira, Angela Rweyora, Mary Kangah, Beatrice Kabaswahili, James Abach, George Abongomera, Joseph Omongin, Irene Aciro, Aleti Philliam, Beatrice Arach, Emmanuel Ocung, Geoffrey Amone, Peter Miles, Claudia Adong, Constance Tumsuiime, Patrick Kidega, Ben Otto, Florence Apio, Keith Baleeta, Andrew Mukuye, Mary Abwola, Fred Ssennono, David Baliruno, Stephen Tuhirwe, Ronald Namisi, Fredrick Kigongo, Dickson Kikyonkyo, Furaha Mushahara, David Okweny, Julian Tusiime, Alex Musiime, Agnes Nankya, Dickens Atwongyeire, Sowal Sirikye, Sula Myalo, Nelson Noowe, Abbas Lugemwa, Mariam Kasozi, Sandra Mwebe, Lorna Atwine, Tapson Senkindu, Ian Natuhurira, Chrispus Katemba, Emily Ninsiima, Moses Acaku, Joy Kyomuhangi, Rogers Ankunda, Deogratious Tukwasibwe, Lillian Ayesiga, James Hakim, Kusum Nathoo, Mutsa Bwakura-Dangarembizi, Andrew Reid, Ennie Chidziva, Tawand Mhute, Gloria Tinago, Joyline Bhiri, Shepherd Mudzingwa, Misheck Phiri, John Steamer, Ruth Nhema, Colin Warambwa, Godfrey Musoro, Shirley Mutsai, Beauty Nemasango, Columbus Moyo, Stuart Chitongo, Kennias Rashirai, Sydney Vhembo, Brian Mlambo, Sanele Nkomani, Buxton Ndemera, Marko Willard, Chipo Berejena, Yeukai Musodza, Patience Matiza, Boniface Mudenge, Vongai Guti, Anthony Etyang, Clara Agutu, Jay Berkley, Kathryn Maitland, Patricia Njuguna, Shalton Mwaringa, Timothy Etyang, Ken Awuondo, Stephen Wale, Jimmy Shangala, Jefwa Kithunga, Salim Mwarumba, Salma Said Maitha, Robert Mutai, Margaret Lozi Lewa, Gabriel Mwambingu, Alfred Mwanzu, Connie Kalama, Helen Latham, Joyce Shikuku, Amos Fondo, Anne Njogu, Connie Khadenge, Bryan Mwakisha, Abraham Siika, Kara Wools-Kaloustian, Winston Nyandiko, Priscilla Chepkorir-Cheruiyot, Allan Sudoi, Simon Wachira, Betty Meli, Mercy Karoney, Agnes Nzioka, Michael Tanui, Martha Mokaya, Wilson Ekiru, Chris Mboya, Dorothy Mwimali, Cecilia Mengich, Julie Choge, Wilfred Injera, Kennedy Njenga, Salinah Cherutich, Millicent Anyango Orido, Gerald Omondi Lwande, Peter Rutto, Alice Mudogo, Irene Kutto, Amina Shali, Linda Jaika, Hellen Jerotich, Mowlem Pierre, Jane Mallewa, Symon Kaunda, Joep Van Oosterhout, Bernadette O'Hare, Robert Heydermann, Carmen Gonzalez, Nettie Dzabala, Christine Kelly, Brigitte Denis, George Selemani, Linda Nyondo- Mipando, Emmie Chirwa, Peter Banda, Linley Mvula, Harrison Msuku, Milton Ziwoya, Yollam Manda, Simon Nicholas, Clemens Masesa, Thandi Mwalukomo, Lumbani Makhaza, Irene Sheha, Joseph Bwanali, Molly Limbuni, Diana M Gibb, Margaret J Thomason, Ann Sarah Walker, Sarah L Pett, Alexander J Szubert, Anna Griffiths, Helen Wilkes, Chathurika Rajapakse, Moira J Spyer, Andrew J Prendergast, Nigel Klein, Mary Rauchenberger, Nadine Van Looy, Emma Little, Keith Fairbrother, Frances Cowan, Janet Seeley, Sarah Bernays, Rachel Kawuma, Zivai Mupambireyi  The Lancet HIV  Volume 5, Issue 5, Pages e231-e240 (May 2018) DOI: 10.1016/S2352-3018(18)30038-9 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 1 Trial profile ART=antiretroviral therapy. RUSF=ready-to-use supplementary food. RUTF=ready-to-use therapeutic food. *Reasons were not mutually exclusive, therefore total is more than the number of patients not randomly assigned treatment. †Considered too unwell (one patient), not able to comply with trial schedule (one patient), and no further details (one patient). ‡Ten patients ineligible after randomisation (four previously received ART, one RUSF contraindicated [milk allergy]), one 3 months pregnant, one had CD4 count ≥100 cells per μL at screening [38 cells per μL at enrolment], one randomly assigned 7 weeks after screening, two incorrect consent [one aged 14 years gave assent but without caregiver consent at enrolment; one aged 19 years old gave assent but caregiver consent was obtained on the basis of a self-reported age of 16 years at screening]). §Four patients assigned no-RUSF and two assigned RUSF were not formally lost to follow-up (they were seen in the clinic within 91 days of week 48). ¶Time-to-event analyses included all times at-risk from randomisation to the earliest of the event or last clinical follow-up if the event had not occurred (details on adherence to randomised strategy in appendix). The Lancet HIV 2018 5, e231-e240DOI: (10.1016/S2352-3018(18)30038-9) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 2 Overall mortality through 48 weeks Dotted vertical line at week 24 when the primary outcome (mortality) was measured. HR=hazard ratio. RUSF=ready-to-use supplementary food. The Lancet HIV 2018 5, e231-e240DOI: (10.1016/S2352-3018(18)30038-9) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 3 Changes in weight, BMI, MUAC, and grip strength hrough 48 weeks Data are mean (95% CI). Figure shows changes in (A) weight, (B) body-mass index (BMI), (C) MUAC (mid-upper-arm-circumference), and (D) grip strength. p values compare changes from baseline across randomised groups, and hence adjust for any imbalances at baseline. Weight, BMI, and MUAC were analysed only in those aged ≥13 years at initiation of antiretroviral therapy. RUSF=ready-to-use supplementary food. The Lancet HIV 2018 5, e231-e240DOI: (10.1016/S2352-3018(18)30038-9) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 4 Changes in body composition through 48 weeks Data are mean (95% CI) for patients aged ≥13 years at initiation of antiretroviral therapy. Figure shows changes in (A) fat mass and (B) fat-free mass. p values compare changes from baseline across randomly assigned groups and hence adjust for any imbalances at baseline. RUSF=ready-to-use supplementary food. The Lancet HIV 2018 5, e231-e240DOI: (10.1016/S2352-3018(18)30038-9) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions